Glycotope GmbH to present advances in GlycoExpress technology at BIO-Europe

NewsGuard 100/100 Score
Nov 12 2010

Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress™ technology of novel human cell lines during the upcoming BIO-Europe in Munich. With two of its glycooptimized antibodies produced by GlycoExpress™ and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress™ for production of biotherapeutics.

This strongly validates this innovative technology for future development and production of therapeutic proteins. The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority. All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).

Source: Glycotope GmbH

 

Posted in: Device / Technology News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses
Empowering Change: How Hologic is Shaping the Future of Women's Healthcare
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates
Personality dictates binge-watching: Study reveals why we can't stop streaming
Novel SARS-CoV-2 mutations found in floodwaters near homeless communities

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations